bioRxivCell BiologyPreprint
Regulator of G Protein Signaling 6 Negatively Regulates Platelet Activation and Arterial Thrombosis in Mice
Renat RoytenbergiD, Boyd R. RorabaughiD, Hong YueiD, Robbie Jividen, Scott J. CameroniD, Wei LiiD
- Citations
- 0
Abstract
BackgroundPlatelet activation via G protein-coupled receptors (GPCRs) is central to arterial thrombosis. P2Y12 is a canonical Gi-coupled receptor mediating ADP-dependent platelet activation, yet the role of Regulator of G protein Signaling 6 (RGS6), a modulator of Gi signaling, in platelet function and thrombosis remains unclear. ObjectivesTo determine the role of RGS6 in platelet activation and arterial thrombosis and to define its impact on P2Y12/Gi signaling. MethodsArterial thrombosis was assessed using a FeCl{square}-induced carotid artery injury model in wild-type (WT) and Rgs6-/- mice. Platelet aggregation was measured ex vivo. Signaling pathways were analyzed by Western blot in ADP-stimulated platelets. P2Y12/Gi signaling was further evaluated using a cAMP-responsive luciferase reporter assay in HEK293 cells. ResultsMale Rgs6-/- mice exhibited significantly accelerated thrombosis compared with WT controls. Rgs6-/- platelets showed enhanced ADP-induced aggregation, whereas collagen-induced aggregation was unchanged. In ADP-stimulated platelets, RGS6 deficiency altered signaling kinetics, characterized by delayed Akt phosphorylation and reduced PKA and VASP phosphorylation. In a heterologous cAMP-luciferase assay, RGS6 attenuated P2Y12/Gi-mediated suppression of cAMP. Two-way ANOVA demonstrated significant effects of ADP and RGS6 expression on luciferase activity, with no interaction, indicating that RGS6 modulates signaling magnitude rather than agonist sensitivity. Pharmacologic inhibition of P2Y12 with clopidogrel abolished the genotype-dependent difference in thrombosis in vivo. ConclusionsRGS6 acts as a negative regulator of platelet P2Y12/Gi signaling and thrombus formation. Loss of RGS6 enhances ADP-dependent platelet activation and accelerates arterial thrombosis, establishing RGS6 as an endogenous brake on platelet activation.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High Mobility Group Box 1 enhances ADP-mediated platelet activation by increasing platelet surface P2Y12 localization
D. Nolfi-Donegan, G. Annarapu, … S. Shiva·bioRxiv·Mar 24, 2021
- Trpc6 gain-of-function disease mutation enhances phosphatidylserine exposure in murine platelets
K. L. Boekell, B. J. Brown, … J. S. Schlondorff·bioRxiv·Feb 1, 2022
- Role of the NO-GC/cGMP signaling pathway in platelet biomechanics
J. G. Rodriguez, A. Balmes, … T. E. Schaffer·bioRxiv·Apr 28, 2023
- RAP1-RHO small GTPase cross-talk mediates integrin-dependent and -independent platelet procoagulant response
Abigail Ballard-Kordeliski, Nikola Ziegmann, … Wolfgang Bergmeier·HaematologicaPeer-reviewed·Mar 5, 2026
- RIP2 inhibits DOCK8-mediated platelet dense granule release and alleviates experimental myocardial infarction
Jianjun Zhang, Guanxing Pan, … Zhongren Ding·bioRxiv·Apr 19, 2025
- Nitric oxide inhibits platelet adhesion to platelet-microparticles through reducing integrin αIIbβ3 activation
Deanna Howley, James Salt, … Wayne Roberts·bioRxiv·Aug 1, 2026